News|Videos|August 11, 2023
EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB
A comprehensive discussion on clinical factors that impact pharmacologic treatment selection in patients with OAB.
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Advertisement
Related to this article
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Kanchi Chadha, MD, FACOG, MSCP, supports reconsidering MHT boxed warnings but says the FDA cited no study behind the change.
HRSA will award up to $1 million to a single organization to update the Women's Preventive Services Guidelines through the new WISH program.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
Diagnosing Sleep Disturbances Beyond VMS in Menopause
3
Reactions to FDA's boxed warning removals for menopausal hormone therapy
4
Q&A: Peter Hsin, BS, on perioperative ketamine and early postpartum depression
5